Abstract: Abstract objective To observe the changes of plasma cardiotrophin-1(CT-1) and N terminal probrain natriuretic (NT-pro BNP) in elderly hypertensive patients with heart failure by phosphocreatine therapy．Methods 76 hypertensive patients with heart failure , aged 65 or over were randomly divided into treatment group and control group (n=38, each)．The control group received routine anti-heart failure treatment. The treatment group received conventional therapy plus creatine phosphate sodium for 2 weeks. Plasma CT-1 and NT-pro BNP were determined in all subjects. Plasma CT-1 level was measured by a double antibody sandwich enzyme-linked immunosorbent assay (ELISA). NT-pro BNP concentration was tested by Pu Rui fluorescent dry quantitative analyzer. Results Plasma CT-1 and NT-pro BNP of two groups were lower after treatment (P＜0.01). The level of Plasma CT-1 and NT-pro BNP in treatment group was significantly decreased than that in control group (P＜0.01, P＜0.05). There was statistic difference in total effective rate ( 89.47% in treatment group /71.05% in control group , P < 0.05). The time needed in improving heart failure symptoms was shorter in treatment group (P < 0.05). Conclusions Conventional therapy plus creatine phosphate sodium decrease plasma CT-1 and NT-pro BNP levels in elderly hypertensive patients with heart failure and this therapy works faster in improving symptoms of heart failure.

Key words: Phosphocreatine, elderly, hypertension, heart failure, cardiotrophin-1, N terminal probrain natriuretic